ArticleBritish journal of cancer2015
Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase.
Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis.The oncologist · 2023Pooled it
- Site-Specific Patterns of Distant Relapse on ^18F-FDG PET/Contrast-Enhanced CT According to Molecular Subtype in Breast Cancer: A Retrospective Cohort Study.Nuclear medicine and molecular imaging · 2026Article
- CA 15.3, Metastatic Burden, and Overall Survival in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: Real-World Evidence from Peru.Biomedicines · 2026Article
- Association between asymptomatic detection of distant metastases and survival in breast cancer: a retrospective cohort study.BMC women's health · 2026Article
- Total Body PET.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Article
- Glucocorticoid receptor: a harmonizer of cellular plasticity in breast cancer-directs the road towards therapy resistance, metastatic progression and recurrence.Cancer metastasis reviews · 2024Review
- Combining metabolomics and machine learning to discover biomarkers for early-stage breast cancer diagnosis.PloS one · 2024Article
- Article
- Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.Molecular diagnosis & therapy · 2023Article
- Differences in Molecular Subtype Reference Standards Impact AI-based Breast Cancer Classification with Dynamic Contrast-enhanced MRI.Radiology · 2023Article
- Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level.Journal of breast cancer · 2023Article
- State of the Art in 2022 PET/CT in Breast Cancer: A Review.Journal of clinical medicine · 2023Review
- Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Prognosis of asymptomatic versus symptomatic metastatic breast cancer: a multicenter retrospective study.Scientific reports · 2022Article
- Significance of serum carcinoembryonic antigen in metastatic breast cancer patients: A prospective study.World journal of clinical oncology · 2022Article
- A Photoacoustic Contrast Agent for miR-21 via NIR Fluorescent Hybridization Chain Reaction.Bioconjugate chemistry · 2022Article
- The double agents in liquid biopsy: promoter and informant biomarkers of early metastases in breast cancer.Molecular cancer · 2022Review
- Radiomics in Breast Cancer: In-Depth Machine Analysis of MR Images of Metastatic Spine Lesion.Sovremennye tekhnologii v meditsine · 2022Article
- The correlation between neutrophil-to-lymphocyte ratio, carcinoembryonic antigen, and carbohydrate antigen 153 levels with chemotherapy-related cognitive impairment in early-stage breast cancer patients.Frontiers in medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollow-up care in breast cancer is still an issue of debate. Diagnostic methods are more sensitive, and more effective therapeutic options are now available. The risk of recurrence is not only influenced by tumour stage but also by the different molecular subtypes. This study was performed to evaluate the use of whole-body imaging combined with tumour marker monitoring for the early detection of asymptomatic metastatic breast cancer (MBC).
methodsThis analysis was performed as part of a follow-up study evaluating 813 patients with a median follow-up of 63 months. After primary therapy, all patients underwent tumour marker monitoring for CEA, CA 15-3 and CA 125 at 6-week intervals within an intensified diagnostic aftercare algorithm. A reproducible previously defined increase was considered as a strong indicator of MBC. From 2007 to 2010, 44 patients with tumour marker increase underwent whole-body magnetic resonance imaging and/or an FDG-PET/CT scan. Histological clarification and/or imaging follow-up were done.
resultsMetastases were detected in 65.9% (29/44) of patients, 13.6% (6/44) had secondary malignancies besides breast cancer and 20.5% (9/44) had no detectable malignancy. Limited disease was found in 24.1% (7/29) of patients. Median progression-free survival of MBC was 9.2 months and median overall survival was 41.1 months. The 3- and 5-year survival rates were 64.2% and 40.0%, respectively.
conclusionsA reproducible tumour marker increase followed by whole-body imaging is highly effective for early detection. By consequence, patients might benefit from earlier detection and improved therapeutic options with a prolonged survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.